Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Liver Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Temozolomide 22Radiotherapy 17Carmustine 9Magnetic Resonance Spectroscopy 8Carboplatin 8Vorinostat 6Surgical Procedures, Operative 6Radiation 6Cisplatin 6Chemotherapy, Adjuvant 6O(6)-benzylguanine 5Erlotinib Hydrochloride 5Cyclophosphamide 5Bevacizumab 5veliparib 4Vincristine 4Thiotepa 4Specimen Handling 4Radiotherapy, Intensity-Modulated 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Lenalidomide 4Filgrastim 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4Radiotherapy, Conformal 3Procarbazine 3Lomustine 3Iodine-125 3Immunoglobulin G 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Astrocytoma × carotuximab × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡